The Q2 2025 biopharma M&A landscape marked a strategic pivot toward targeted, mid-sized acquisitions, following a high-volume Q1. Leading firms focused on enhancing pipelines in high-growth therapeutic areas through selective, high-impact deals. Sanofi led the quarter with its $9.5 billion acquisition of Blueprint Medicines, adding commercial-stage oncology drug Ayvakit and two clinical candidates in inflammation. AbbVie followed with a $2.1 billion acquisition of Capstan Therapeutics, strengthening its cell and gene therapy capabilities via Capstan’s in vivo CAR-T platform and RNA delivery technology.
Novartis expanded its rare disease portfolio by acquiring Regulus Therapeutics for $1.7 billion, securing the RNA-based candidate farabursen for kidney disease. In April, Veraxa Biotech announced a $1.6 billion SPAC merger with Voyager Acquisition Corp., positioning itself for oncology-focused public growth. Eli Lilly also advanced its genetic medicine strategy with a $1.3 billion deal for Verve Therapeutics, gaining precision therapies for inherited cardiovascular conditions.
In Q2 2025, biopharma therapeutics and platform companies completed 26 M&A transactions totaling $19.3 billion, with $17.1 billion in cash. The average deal size, combining upfront and equity, stood at $1.4 billion.
While the number of deals rose slightly from Q1’s 24 to 26 in Q2, total deal value declined significantly. Transaction value dropped 47% from $36.6 billion, and cash payments fell 33% from $25.4 billion. The average upfront payment also decreased by approximately 10%, from $1.6 billion to $1.4 billion.
The trend shifted toward a higher volume of mid-cap acquisitions in Q2, following Q1’s focus on large-scale deals. This brought the H1 2025 totals to 50 M&A transactions valued at $55.9 billion, including $42.5 billion in cash.
Biopharma M&A, Top Modalities – Q2 2025
During Q2 2025, small-molecule acquisitions led the M&A landscape, making up 13 of 35 deals (37%) and accounting for $12.4 billion or 35% of total deal value. Buyers committed $11.5 billion in upfront or equity-heavy terms, reflecting a strong 93% cash-to-headline ratio. While biologics targets saw the most activity with 14 deals (40%), they generated just $4.9 billion in value (14%), indicating a tilt toward smaller antibody and protein-focused plays rather than large-scale mergers. Notably, a single gene therapy deal stood out at $2.1 billion, fully paid upfront. Similarly, a CRISPR acquisition totaled $1.3 billion, with $1 billion upfront, reinforcing demand for precision-editing platforms. In contrast, cell therapy attracted 6 deals totaling $300 million.
Top M&A – Q2 2025 Review
Sanofi acquiring Blueprint Medicines – June 2025
Sanofi acquired Blueprint Medicines for $9.5 billion, including $9.1 billion upfront and up to $400 million in milestones. The $129 per share offer represented a 27% premium. The deal adds Ayvakit (approved for GIST and systemic mastocytosis), Phase III elenestinib, and Phase II BLU-808 to Sanofi’s pipeline, along with early-stage assets targeting cancer and inflammatory conditions. Blueprint shares have been delisted from NASDAQ.
AbbVie acquiring Capstan – June 2025
AbbVie is acquiring Capstan in a deal worth up to $2.1 billion in upfront cash, subject to adjustments. Capstan’s pipeline includes CPTX-2309, a Phase I in vivo tLNP anti-CD19 CAR-T therapy for autoimmune diseases, and CPTX-2506, a discovery-stage CAR-T targeting BCMA for cancer and autoimmune indications. The deal also brings Capstan’s tLNP platform for RNA delivery and multiple early-stage programs in immunology, cancer, and fibrosis.
Novartis acquiring Regulus Therapeutics – April 2025
Novartis acquired Regulus Therapeutics for up to $1.7 billion, including $800 million upfront ($7.00 per share, 108% premium) and a $900 million contingent value right tied to the approval of lead asset farabursen. Farabursen, a Phase Ib RNA therapy, targets autosomal dominant polycystic kidney disease (ADPKD). The deal also includes early-stage programs in nephrology and CNS. Regulus shares have been delisted following completion.
Veraxa Biotech reverse merging with Voyager Acquisition Corp. in a SPAC – April 2025
Veraxa Biotech is merging with Voyager Acquisition Corp. in a SPAC deal to form a publicly listed company under the ticker VERX on NASDAQ. The transaction values Veraxa at a pre-money equity value of $1.3 billion, with a pro forma equity value of $1.6 billion and up to $253 million in Voyager’s trust. Veraxa will hold 79.2% of the combined company, Voyager shareholders 19.3%, and PIPE investors 1.5%. The merged company will focus on ADCs and bispecific T-cell therapies, including Phase I FLT3-targeting VX-A901 for AML and multiple preclinical and discovery-stage oncology programs.
Eli Lilly acquiring Verve Therapeutics – June 2025
Eli Lilly is acquiring Verve Therapeutics for $1 billion upfront ($10.50/share, 67.5% premium) with a potential $300 million contingent value right (CVR), bringing the total deal value to $1.3 billion. Verve’s pipeline includes Phase II VX-864 for AAT deficiency, Phase I VERVE-102 for hyperlipoproteinaemia, and several preclinical and partnered programs targeting atherosclerosis, familial hypercholesterolemia, and liver and cardiovascular diseases. The acquisition strengthens Lilly’s cardiometabolic portfolio and supports its strategy to shift from chronic treatments to single-course genetic therapies.
Also check out Biopharma Therapeutics and Platform R&D Partnerships – Q2 2025
